Innovent and Lilly Announce Expansion of TYVYT(R) (Sintilimab Injection) Licensing Agreement

SUZHOU, China and INDIANAPOLIS, Aug. 18, 2020 -- (Healthcare Sales & Marketing Network) -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality m... Biopharmaceuticals, Oncology, Licensing Innovent Biologics, Eli Lilly, TYVYT, sintilimab, NSCLC

https://salesandmarketingnetwork.com/news_release_bs.html?ID=2046231

Source: HSMN NewsFeed - August 18, 2020 Category: Pharmaceuticals Source Type: news

More News: Cancer & Oncology | China Health | Marketing | Non-Small Cell Lung Cancer | Pharmaceuticals